



PCR233

Lorena Lopez-Gonzalez¹, Sean D. MacKnight², François Laliberté², Robert C. Schell³, Sandra Nestler-Parr¹, Meri LiVecchi¹, Patrick Gillard¹


¹BioCryst Pharmaceuticals, Durham, NC, USA; ²Groupe d'Analyse, Ltée, Montreal, QC, Canada; ³Analysis Group, Inc., Menlo Park, CA, USA

EU ISPOR 2024 Poster – Supplemental Material





Figure S1. Eligibility Criteria and Patient Disposition



CI-INH, CI-in hibitor; HAE, hereditary angioedema; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification.